[{"id":"f25cf478-f7d0-48ec-a823-1e8a5b6955d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04764474","created_at":"2022-03-09T14:53:09.433Z","updated_at":"2024-07-02T16:35:19.376Z","phase":"Phase 1","brief_title":"A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH","source_id_and_acronym":"NCT04764474","lead_sponsor":"Hutchmed","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ranosidenib (HMPL-306)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 02/28/2021","start_date":" 02/28/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-02-14"},{"id":"f903fd24-26e3-4fb8-bab2-2becf6cfbc45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04272957","created_at":"2021-01-18T20:45:21.874Z","updated_at":"2024-07-02T16:36:44.139Z","phase":"Phase 1","brief_title":"A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms","source_id_and_acronym":"NCT04272957","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ranosidenib (HMPL-306)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 05/14/2020","start_date":" 05/14/2020","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2020-06-16"}]